U.S., April 25 -- ClinicalTrials.gov registry received information related to the study (NCT06941818) titled 'HS-IT101 Injection in the Treatment of Advanced Melanoma' on April 15.
Brief Summary: Single-arm, open-label,interventional study evaluating adoptive cell therapy (ACT) with autologous tumor-infiltrating lymphocyte (TIL) infusion (HS-IT101) after lymphodepletion preparative with fludarabine and cyclophosphamide regimen, followed by IL-2, for the treatment of patients with advanced melanoma.
Study Start Date: June 10
Study Type: INTERVENTIONAL
Condition:
Advanced Melanoma
Intervention:
DRUG: HS-IT101 Injection
Adoptive transfer of 5x10^9-6x10^10 autologous TIL to patients i.v. in 30-60 minutes.
Recruitment Status: NOT_YET_RE...